Meeting
2015 Breast Cancer Symposium
Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).
Authors
Shannon Leigh Huggins-Puhalla
University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA
Shannon Leigh Huggins-Puhalla , Hyo S. Han , Véronique Diéras , Michael Friedlander , George Somlo , Banu Arun , Hans Wildiers , Bella Kaufman , Jean-Pierre M. Ayoub , Melissa Shah , David Burmedi , Qin Qin , Jane Qian , Vincent L. Giranda , Stacie Peacock Shepherd
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Systemic Therapy, Survivorship, and Health Policy
Track
Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02163694
Citation
J Clin Oncol 33, 2015 (suppl 28S; abstr 155)
DOI
10.1200/jco.2015.33.28_suppl.155
Abstract #
155
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2‒BRCA-associated locally advanced or metastatic breast cancer (BC).
First Author: Shannon Puhalla
Poster
2020 ASCO Virtual Scientific Program
Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.
First Author: Shannon L Puhalla
Poster
2020 ASCO Virtual Scientific Program
Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.
First Author: Hyo S. Han
Poster
2018 ASCO Annual Meeting
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).
First Author: Joyce O'Shaughnessy